We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Rahul Agarwal, Director, Wealth Discovery, explains how the once beaten-down sector, has recently witnessed sharp uptick with majority of stocks gaining 10 to 40 per cent within a month, and why investors should look into this space.
Investors ended 2018 with a sour outlook for biopharma, as fourth-quarter economic worries erased massive share-price gains the sector had enjoyed in the first half of the year. Dealmaking was down during the year, as were licensing deals.
US politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their shares to drop suddenly.